




RealRate

PHARMACEUTICAL 2014

Aegerion Pharmaceuticals Inc
Rank 75 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Aegerion Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aegerion Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Aegerion Pharmaceuticals Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 311%, being 69% points above the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	140,514
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,844
Liabilities, Non-Current	4,011
Other Assets	164
Other Compr. Net Income	11
Other Expenses	6,092
Other Liabilities	445
Other Net Income	58
Other Revenues	48,546
Property and Equipment	1,654
Research and Development	29,788
Selling, General and Administrative Expense	76,082

Output Variable	Value in 1000 USD
Assets	142,332
Liabilities	29,300
Expenses	111,962
Revenues	48,546
Stockholders Equity	113,032
Net Income	-63,358
Comprehensive Net Income	-63,352
BaseVar	166,104
ECR before LimitedLiability	213%
Economic Capital Ratio	311%